23031-32-5 Usage
Description
Different sources of media describe the Description of 23031-32-5 differently. You can refer to the following data:
1. Terbutaline is the N-t-butyl analogue of metaproterenol and, as such, would be expected to have a more potent β2-selectivity. When compared to metaproterenol, terbutaline has a threefold greater potency at the β2-receptor. Like metaproterenol, it is resistant to COMT and slowly metabolized by MAO, therefore having good oral bioavailability with similar onset and duration. Terbutaline is available as tablets and solutions for injection and inhalation. Adverse effects are similar to other direct-acting β2-selective agonists, however, with a greater incidence of palp
2. Terbutaline (hemisulfate) (Item No. 21292) is an analytical reference standard categorized as a β2-adrenergic receptor agonist. Terbutaline has been used to enhance physical performance in athletes. This product is intended for use in analytical forensic applications. This product is also available as a general research tool .
Chemical Properties
White or almost white, crystalline powder.
Uses
Different sources of media describe the Uses of 23031-32-5 differently. You can refer to the following data:
1. betaadrenergic agonist, bronchodilator
2. Anti Asthmatic
3. Terbutaline Sulfate is derived from the starting material, Terbutaline Hemisulfate Salt (T109750), which is a β-adrenergic receptor agonist. A Bronchodilator; Metabolite of Terbutaline (T109763).
Brand name
Terbutaline is INN and
BAN.
Therapeutic Function
Bronchodilator
Clinical Use
Beta2
-adrenoceptor agonist:
Reversible airways obstruction
Veterinary Drugs and Treatments
Terbutaline is used as a bronchodilating agent in the adjunctive
treatment of cardiopulmonary diseases (including tracheobronchitis,
collapsing trachea, pulmonary edema, and allergic bronchitis)
in small animals. It may be of some benefit in treating bradyarrhythmias
in dogs and cats.
Terbutaline has been used occasionally in horses for its bronchodilating
effects, but adverse effects, short duration of activity after
IV administration and poor oral absorption have limited its use.
It has been shown to be useful as a diagnostic agent to diagnose
anhidrosis in horses after intradermal injection.
Oral and intravenous terbutaline has been used successfully in
humans for the inhibition of premature labor clinical signs.
Drug interactions
Potentially hazardous interactions with other drugs
Effect may be diminished by beta-blockers.
Theophylline: increased risk of hypokalaemia.
Metabolism
Terbutaline undergoes extensive first-pass metabolism
by sulphate (and some glucuronide) conjugation in the
liver and the gut wall. It is excreted in the urine and faeces
partly as the inactive sulphate conjugate and partly as
unchanged terbutaline, the ratio depending upon the
route by which it is given.
Check Digit Verification of cas no
The CAS Registry Mumber 23031-32-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,0,3 and 1 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 23031-32:
(7*2)+(6*3)+(5*0)+(4*3)+(3*1)+(2*3)+(1*2)=55
55 % 10 = 5
So 23031-32-5 is a valid CAS Registry Number.
InChI:InChI=1/2C12H19NO3.H2O4S/c2*1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8;1-5(2,3)4/h2*4-6,11,13-16H,7H2,1-3H3;(H2,1,2,3,4)
23031-32-5Relevant articles and documents
Preparation method of terbutaline sulfate and B crystal form thereof
-
Paragraph 0020; 0039; 0048-0053; 0054; 0060-0063, (2021/01/29)
The invention relates to a preparation method of terbutaline sulfate and a B crystal form thereof, which comprises the following steps: sequentially carrying out bromination, reduction reaction and substitution reaction to obtain 1-[3, 5-bis (benzyloxy) phenyl]-2-(tert-butylamino) ethanol; reacting 1-[3, 5-di (benzyloxy) phenyl]-2-(tert-butylamino) ethanol with a reducing agent and a catalyst, performing salifying with sulfuric acid to obtain a terbutaline sulfate crude product, and crystallizing the terbutaline sulfate crude product under a heating reflux condition to obtain the terbutaline sulfate medicinal B crystal form. Raw materials and auxiliary materials used in the method are cheap and easy to obtain, highly toxic and explosive reagents are avoided in the reaction process, the whole reaction route is short, operation is easy and convenient, reaction conditions are mild and safe, the yield of the obtained finished product terbutaline sulfate and the medicinal B crystal form thereof is high, the yield of terbutaline sulfate is 83% or above, and the yield of the medicinal B crystal form is 70% or above, and industrialized production can be achieved easily.
Preparation method of terbutaline sulfate
-
Paragraph 0017; 0029; 0033-0034; 0038-0039; 0043-0044; 0048, (2020/04/29)
The invention discloses a preparation method of terbutaline sulfate, wherein the method comprises the following steps: carrying out a bromination reaction on 3,5-dihydroxyacetophenone as a raw material by using a bromination reagent without hydroxyl protection, carrying out reduction and ring closing, carrying out a ring-opening reaction with tert-butylamine, and finally forming a salt with sulfuric acid to obtain terbutaline sulfate. According to the method, the defects of requirement of deprotection after hydroxyl protection, use of various high-risk highly toxic reagents, long reaction stepand low yield in the prior art are overcome.
